Intraductal carcinoma of the prostate - Revision history

Michael at 14:54, 4 August 2022

2022-08-04T14:54:05Z

← Older revision		Revision as of 14:54, 4 August 2022
Line 119:		Line 119:
	==IHC==		==IHC==
	Features - basal cells present:		Features - basal cells present:
	*CK34betaE12 +ve.		*[[CK34betaE12]] +ve.
	*p63 +ve.		*[[p63]] +ve.

	==Molecular==		==Molecular==

Michael at 22:30, 9 October 2021

2021-10-09T22:30:52Z

← Older revision		Revision as of 22:30, 9 October 2021
Line 126:		Line 126:

	Note:		Note:
	*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal \|~~vauthors~~=Ibrahim M, Yadav S, Ogunleye F, Zakalik D \|title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum \|journal=BMC Cancer \|volume=18 \|issue=1 \|pages=179 \|date=February 2018 \|pmid=29433453 \|pmc=5809938 \|doi=10.1186/s12885-018-4098-y \|url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref>		*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal \|authors=Ibrahim M, Yadav S, Ogunleye F, Zakalik D \|title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum \|journal=BMC Cancer \|volume=18 \|issue=1 \|pages=179 \|date=February 2018 \|pmid=29433453 \|pmc=5809938 \|doi=10.1186/s12885-018-4098-y \|url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref>

	==See also==		==See also==

Michael: /* Molecular */

2021-04-26T18:53:42Z

Molecular

← Older revision		Revision as of 18:53, 26 April 2021
Line 124:		Line 124:
	==Molecular==		==Molecular==
	*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal \|authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG \|title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories \|journal=Nat Commun \|volume=8 \|issue= \|pages=13671 \|date=January 2017 \|pmid=28067867 \|pmc=5227331 \|doi=10.1038/ncomms13671 \|url=}}</ref>		*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal \|authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG \|title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories \|journal=Nat Commun \|volume=8 \|issue= \|pages=13671 \|date=January 2017 \|pmid=28067867 \|pmc=5227331 \|doi=10.1038/ncomms13671 \|url=}}</ref>

			Note:
			*BRCA1 associated prostate cancer seems to be less common/less studied.<ref name=pmid29433453>{{cite journal \|vauthors=Ibrahim M, Yadav S, Ogunleye F, Zakalik D \|title=Male BRCA mutation carriers: clinical characteristics and cancer spectrum \|journal=BMC Cancer \|volume=18 \|issue=1 \|pages=179 \|date=February 2018 \|pmid=29433453 \|pmc=5809938 \|doi=10.1186/s12885-018-4098-y \|url=https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4098-y }}</ref>

	==See also==		==See also==

Michael: /* Molecular */

2021-04-26T18:26:39Z

Molecular

← Older revision		Revision as of 18:26, 26 April 2021
Line 123:		Line 123:

	==Molecular==		==Molecular==
	*+/-BRCA2 mutation.<ref name=pmid28067867>{{cite journal \|authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG \|title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories \|journal=Nat Commun \|volume=8 \|issue= \|pages=13671 \|date=January 2017 \|pmid=28067867 \|pmc=5227331 \|doi=10.1038/ncomms13671 \|url=}}</ref>		*+/-[[BRCA2 mutation]].<ref name=pmid28067867>{{cite journal \|authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG \|title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories \|journal=Nat Commun \|volume=8 \|issue= \|pages=13671 \|date=January 2017 \|pmid=28067867 \|pmc=5227331 \|doi=10.1038/ncomms13671 \|url=}}</ref>

	==See also==		==See also==

Michael: /* Molecular */

2021-04-26T18:26:15Z

Molecular

← Older revision		Revision as of 18:26, 26 April 2021
Line 123:		Line 123:

	==Molecular==		==Molecular==
	*+/-BRCA2 mutation.		*+/-BRCA2 mutation.<ref name=pmid28067867>{{cite journal \|authors=Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG \|title=Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories \|journal=Nat Commun \|volume=8 \|issue= \|pages=13671 \|date=January 2017 \|pmid=28067867 \|pmc=5227331 \|doi=10.1038/ncomms13671 \|url=}}</ref>

	==See also==		==See also==

Michael at 20:59, 6 April 2021

2021-04-06T20:59:26Z

← Older revision		Revision as of 20:59, 6 April 2021
Line 11:		Line 11:
	\| IHC = basal cells are present (CK34betaE12 +ve, p63 +ve)		\| IHC = basal cells are present (CK34betaE12 +ve, p63 +ve)
	\| EM =		\| EM =
	\| Molecular =		\| Molecular = +/-BRCA2 mutation
	\| IF =		\| IF =
	\| Gross =		\| Gross =
Line 17:		Line 17:
	\| Site = [[prostate gland]]		\| Site = [[prostate gland]]
	\| Assdx =		\| Assdx =
	\| Syndromes =		\| Syndromes =
	\| Clinicalhx =		\| Clinicalhx =
	\| Signs =		\| Signs =
Line 27:		Line 27:
	\| Prognosis = poor, strongly suggestive invasion if not present		\| Prognosis = poor, strongly suggestive invasion if not present
	\| Other =		\| Other =
	\| ClinDDx =		\| ClinDDx =
	\| Tx =		\| Tx =
	}}		}}
Line 121:		Line 121:
	*CK34betaE12 +ve.		*CK34betaE12 +ve.
	*p63 +ve.		*p63 +ve.

			==Molecular==
			*+/-BRCA2 mutation.

	==See also==		==See also==

Michael: /* See also */

2018-08-28T20:53:11Z

Michael: /* Prevalence */

2018-04-13T19:08:49Z

Prevalence

← Older revision		Revision as of 19:08, 13 April 2018
Line 60:		Line 60:
	\| 56%		\| 56%
	\|}		\|}
	† WHO1 = WHO grade group 1 (Gleason score 6), WHO2 = WHO grade group 2 or 3 (Gleason score 7 (3+4 or 4+3), WHO3 = WHO grade group 4 or 5 (Gleason score 8, 9 or 10)		† WHO1 = WHO [[prostate cancer grading\|grade group]] 1 (Gleason score 6), WHO2 = WHO grade group 2 or 3 (Gleason score 7 (3+4 or 4+3), WHO3 = WHO grade group 4 or 5 (Gleason score 8, 9 or 10)

	==Microscopic==		==Microscopic==

Michael: /* Prevalence */

2018-04-13T19:07:13Z

Prevalence

← Older revision		Revision as of 19:07, 13 April 2018
Line 57:		Line 57:
	\| 37%		\| 37%
	\|-		\|-
	\| Metastasis or recurrence		\| Metastasis or biochemical recurrence
	\| 56%		\| 56%
	\|}		\|}

Michael: /* Prevalence */

2018-04-13T19:06:59Z

Prevalence

← Older revision		Revision as of 19:06, 13 April 2018
Line 48:		Line 48:
	! Prevalence		! Prevalence
	\|-		\|-
	\| ~~WHO1†~~		\| WHO1 †
	\| 2%		\| 2%
	\|-		\|-
	\| ~~WHO2†~~ or ~~WHO3†~~		\| WHO2 † or WHO3 †
	\| 23%		\| 23%
	\|-		\|-
	\| ~~WHO4†~~ or ~~WHO5†~~		\| WHO4 † or WHO5 †
	\| 37%		\| 37%
	\|-		\|-

← Older revision		Revision as of 20:53, 28 August 2018
Line 126:		Line 126:
	*[[Prostate carcinoma]].		*[[Prostate carcinoma]].
	*[[Ductal adenocarcinoma of the prostate]].		*[[Ductal adenocarcinoma of the prostate]].
			*[[Cribriform pattern within invasive prostate carcinoma]].

	==References==		==References==